Boothbay Fund Management, LLC T Scan Therapeutics, Inc. Transaction History
Boothbay Fund Management, LLC
- $3.28 Billion
- Q1 2025
A detailed history of Boothbay Fund Management, LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 16,242 shares of TCRX stock, worth $23,875. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,242Holding current value
$23,875% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
92Shares Held
39.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$7.88 Million2.73% of portfolio
-
Bvf Inc San Francisco, CA4.89MShares$7.19 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$6.56 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.15 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.09 Million0.05% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $27.8M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...